Kyowa Kirin has received approval from the FDA for a dosing update to the Crysvita prescribing information, introducing a new option for adults with XLH.

Four cancer drugs have got the FDA nod in May thus far, with approvals spanning haematological and solid tumour indications.

AstraZeneca’s Imfinzi (durvalumab) will become the first immunotherapy available for UK National Health Service (NHS) patients with an aggressive form of stomach cancer, after a ...

Hundreds of biopharma leaders say Dr Richard Pazdur has the necessary qualities to lead the FDA amid a crisis of confidence.

Arna Pharma and Slate Run Pharmaceuticals have completed a JV to form a company focusing on branded products and 505(b)(2) medicines.

During ECO 2026, a study was presented analysing the use of tirzepatide, a dual GIP and GLP-1 agonist, in treating type 1 diabetes (T1D).

OTXL’s COO, Beth White, notes that the CGT marketplace could revitalise programmes that would otherwise have been indefinitely put on ice.

Pfizer has received EC approval to expand the Hympavzi indication to treat haemophilia A or B with inhibitors in patients aged 12 years and over.

At ECO 2026, findings from a post-hoc indirect treatment comparison of Wegovy versus Foundayo, oral GLP-1RAs approved in the US for chronic weight management.

At ECO 2026, data from the SURMOUNT-MAINTAIN trial evaluating the use of Eli Lilly's Zepbound (tirzepatide) in sustaining weight loss was presented.

Zydus Lifesciences is set to acquire all outstanding Assertio common shares in a $166.4m deal, via its subsidiary Zydus Worldwide DMCC.

Coya Therapeutics has received fast track designation from the US FDA for COYA 302, an investigational biologic combination therapy to treat ALS.